U.S. Capital Markets Stock News

NasdaqGS:PCB
NasdaqGS:PCBBanks

November 2025's Top Dividend Stocks To Consider

As of early November 2025, major U.S. stock indexes have experienced a sharp decline, with technology stocks leading the downturn amid broader market volatility and ongoing economic uncertainties such as the prolonged government shutdown. In this environment, dividend stocks can offer a degree of stability and income potential for investors seeking to navigate these turbulent times by focusing on companies with strong fundamentals and consistent dividend payouts.
NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

Madrigal Pharmaceuticals (MDGL): Forecasts Point to 34.8% Annual Revenue Growth Ahead of Earnings

Madrigal Pharmaceuticals (MDGL) remains in the red, with losses widening at a 15.3% annual rate over the last five years and net profit margins not improving in that period. Looking ahead, analysts forecast annual revenue growth of 34.8% and earnings growth of 67.2% per year, setting the company on a path to profitability within three years. This represents a much faster trajectory than the US market’s projected 10.5% revenue growth. With shares trading below an estimated fair value and the...
NasdaqGS:HALO
NasdaqGS:HALOBiotechs

Halozyme Therapeutics (HALO) Profit Margin Jumps to 47.9%, Reinforcing Bullish Narratives

Halozyme Therapeutics (HALO) posted net profit margins of 47.9%, a significant jump from last year’s 41.4%, as earnings growth for the year hit 51.7%. This figure is twice its five-year average of 20.8% per year. Looking ahead, analysts expect earnings and revenue to continue rising by around 11.6% annually. The company’s price-to-earnings ratio of 13.4x sits comfortably below both the US biotech average of 16.9x and peers at 19.6x. Investors are eyeing the combination of strong...
NasdaqGM:AUPH
NasdaqGM:AUPHBiotechs

Aurinia Pharmaceuticals (AUPH): Profitability Flips, Outpacing Market Growth Expectations and Reinforcing Bullish Narratives

Aurinia Pharmaceuticals (AUPH) has flipped to profitability after five years of transformation, posting average annual earnings growth of 43.8%. Forward guidance points to EPS growth of 17.13% per year and revenue growth of 12.5% per year, both topping the US market average of 10.5%. Improving net profit margins and high-quality earnings continue to shape investor sentiment heading into the latest results. See our full analysis for Aurinia Pharmaceuticals. Next, we will see how these...
NYSE:TAP
NYSE:TAPBeverage

Molson Coors (TAP): Loss Reductions and Earnings Growth Forecast Challenge Bearish Narratives

Molson Coors Beverage (TAP) is forecast to turn profitable within the next three years, with projected earnings growth of 65.59% annually. Revenue, however, is expected to rise just 0.6% per year, well below the US market average of 10.5%. While the company remains unprofitable in the latest results, losses have declined at an annual rate of 17.4% over the past five years. At $43.67 per share, TAP trades at a price-to-sales multiple of 0.8x, below both peer and sector averages, and notably...
NYSE:BCO
NYSE:BCOCommercial Services

Is Brink's Recent 8% Drop a Long-Term Opportunity for Investors in 2025?

Wondering if Brink's is truly a bargain or if recent buzz is just noise? Let’s cut through the headlines and get straight into what matters for value-focused investors. After a sharp drop of 8.2% in the past week and a 7.8% dip over the past month, Brink's still boasts long-term gains, up 14.6% year-to-date and 107.6% over five years. Much of this recent volatility tracks broader market swings and reactions to industry-wide security developments. Investor sentiment has shifted in response to...